Page last updated: 2024-11-02

phentermine and Prader-Willi Syndrome

phentermine has been researched along with Prader-Willi Syndrome in 1 studies

Phentermine: A central nervous system stimulant and sympathomimetic with actions and uses similar to those of DEXTROAMPHETAMINE. It has been used most frequently in the treatment of obesity.

Prader-Willi Syndrome: An autosomal dominant disorder caused by deletion of the proximal long arm of the paternal chromosome 15 (15q11-q13) or by inheritance of both of the pair of chromosomes 15 from the mother (UNIPARENTAL DISOMY) which are imprinted (GENETIC IMPRINTING) and hence silenced. Clinical manifestations include MENTAL RETARDATION; MUSCULAR HYPOTONIA; HYPERPHAGIA; OBESITY; short stature; HYPOGONADISM; STRABISMUS; and HYPERSOMNOLENCE. (Menkes, Textbook of Child Neurology, 5th ed, p229)

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's1 (100.00)2.80

Authors

AuthorsStudies
Nolan, BJ1
Proietto, J1
Sumithran, P1

Other Studies

1 other study available for phentermine and Prader-Willi Syndrome

ArticleYear
Intensive management of obesity in people with Prader-Willi syndrome.
    Endocrine, 2022, Volume: 77, Issue:1

    Topics: Child; Humans; Liraglutide; Obesity; Phentermine; Prader-Willi Syndrome; Retrospective Studies; Topi

2022